← All trials
NCT05838716
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 29, 2023
- Primary completion
- May 31, 2026
- Completion date
- May 31, 2027
- First posted
- May 1, 2023
- Last posted
- Nov 22, 2023
- Enrollment
- 366
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of RochesterLead sponsor
- National Cancer Institute (NCI)Collaborator
- University of RochesterOverall official - principal investigator
- University of RochesterReponsible party - principal investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.